$CCEL
CRYO CELL INTERNATIONAL INC

2020 Q2 Form 10-Q Financial Statement

#000119312520191169 Filed on July 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $7.872M $8.128M $7.495M
YoY Change -3.15% 24.56% 20.34%
Cost Of Revenue $2.481M $2.628M $2.466M
YoY Change -5.62% 47.89% 53.99%
Gross Profit $5.391M $5.500M $5.029M
YoY Change -1.97% 15.82% 8.69%
Gross Profit Margin 68.49% 67.66% 67.1%
Selling, General & Admin $3.559M $3.648M $3.745M
YoY Change -2.45% 3.25% 4.34%
% of Gross Profit 66.01% 66.33% 74.48%
Research & Development $9.821K $4.957K $5.884K
YoY Change 98.12% -83.07% -56.12%
% of Gross Profit 0.18% 0.09% 0.12%
Depreciation & Amortization $95.11K $103.4K $104.9K
YoY Change -8.04% 72.38% 74.78%
% of Gross Profit 1.76% 1.88% 2.09%
Operating Expenses $3.568M $3.653M $3.751M
YoY Change -2.31% 2.54% 4.11%
Operating Profit $1.752M $496.6K $853.7K
YoY Change 252.86% -56.81% -13.52%
Interest Expense $365.4K $424.3K $406.9K
YoY Change -13.89% 39.52% 44.83%
% of Operating Profit 20.85% 85.44% 47.67%
Other Income/Expense, Net -$418.8K -$391.9K -$473.1K
YoY Change 6.86% 33.18% 50.41%
Pretax Income $1.333M $104.6K $380.5K
YoY Change 1174.52% -87.77% -43.42%
Income Tax $380.0K $50.94K $104.7K
% Of Pretax Income 28.5% 48.7% 27.5%
Net Earnings $953.3K $53.67K $275.9K
YoY Change 1676.2% -90.05% -110.9%
Net Earnings / Revenue 12.11% 0.66% 3.68%
Basic Earnings Per Share $0.13 $0.01 $0.04
Diluted Earnings Per Share $0.12 $0.01 $0.03
COMMON SHARES
Basic Shares Outstanding 7.546M 7.803M 7.801M
Diluted Shares Outstanding 8.112M 8.421M 8.425M

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.325M $7.308M $7.884M
YoY Change 27.59% 2.79% 4.01%
Cash & Equivalents $8.420M $6.469M $7.076M
Short-Term Investments $905.4K $839.8K $808.5K
Other Short-Term Assets $241.9K $278.1K $204.9K
YoY Change -13.04% 46.07% -4.17%
Inventory $1.054M $1.046M $16.13M
Prepaid Expenses $684.9K $610.6K $460.6K
Receivables $5.974M $5.867M $5.694M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $17.28M $15.00M $30.38M
YoY Change 15.18% 15.07% 126.83%
LONG-TERM ASSETS
Property, Plant & Equipment $1.739M $1.748M $1.465M
YoY Change -0.52% 68.37% 34.74%
Goodwill $1.941M $1.941M $1.941M
YoY Change 0.0%
Intangibles $1.215M $1.288M $1.314M
YoY Change -5.6% 218.6% 216.53%
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0%
Other Assets $25.82M $24.14M $11.50M
YoY Change 6.97% 196.37% 54.75%
Total Long-Term Assets $27.56M $25.89M $12.97M
YoY Change 6.46% 181.91% 52.2%
TOTAL ASSETS
Total Short-Term Assets $17.28M $15.00M $30.38M
Total Long-Term Assets $27.56M $25.89M $12.97M
Total Assets $44.84M $40.89M $43.34M
YoY Change 9.66% 84.02% 97.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $951.9K $1.029M $1.010M
YoY Change -7.5% -7.56% -15.65%
Accrued Expenses $1.939M $965.0K $2.902M
YoY Change 100.91% -55.78% 1.26%
Deferred Revenue $8.840M $8.365M $8.267M
YoY Change 5.67%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.100M $3.100M
YoY Change 0.0% 55.0% 55.0%
Total Short-Term Liabilities $15.10M $13.61M $15.28M
YoY Change 10.93% 6.35% 14.77%
LONG-TERM LIABILITIES
Long-Term Debt $4.353M $1.425M $1.425M
YoY Change 205.47% 0.0% 0.0%
Other Long-Term Liabilities $34.72M $35.37M $36.30M
YoY Change -1.83% 50.38% 58.13%
Total Long-Term Liabilities $34.72M $36.80M $37.72M
YoY Change -5.63% 47.5% 54.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.10M $13.61M $15.28M
Total Long-Term Liabilities $34.72M $36.80M $37.72M
Total Liabilities $49.82M $48.98M $51.58M
YoY Change 1.72% 34.86% 42.21%
SHAREHOLDERS EQUITY
Retained Earnings -$20.80M -$24.41M -$24.46M
YoY Change -14.76% -7.78% -9.43%
Common Stock $36.38M $35.88M $35.80M
YoY Change 1.4% 12.93% 11.65%
Preferred Stock
YoY Change
Treasury Stock (at cost) $20.56M $19.57M $19.57M
YoY Change 5.07% 0.0% 0.0%
Treasury Stock Shares $6.094M $5.801M 5.801M shares
Shareholders Equity -$4.983M -$8.094M -$8.234M
YoY Change
Total Liabilities & Shareholders Equity $44.84M $40.89M $43.34M
YoY Change 9.66% 84.02% 97.81%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income $953.3K $53.67K $275.9K
YoY Change 1676.2% -90.05% -110.9%
Depreciation, Depletion And Amortization $95.11K $103.4K $104.9K
YoY Change -8.04% 72.38% 74.78%
Cash From Operating Activities $822.2K $527.7K $1.854M
YoY Change 55.81% 1658.93% 9.59%
INVESTING ACTIVITIES
Capital Expenditures -$43.27K -$359.8K $49.09K
YoY Change -87.97% -80.65%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$43.27K -$359.8K -$49.09K
YoY Change -87.97% -3697.8% -89.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -775.0K -775.0K -769.3K
YoY Change 0.0% 55.0% 54.56%
NET CHANGE
Cash From Operating Activities 822.2K 527.7K 1.854M
Cash From Investing Activities -43.27K -359.8K -49.09K
Cash From Financing Activities -775.0K -775.0K -769.3K
Net Change In Cash 3.930K -607.1K 1.036M
YoY Change -100.65% 31.98% 45.41%
FREE CASH FLOW
Cash From Operating Activities $822.2K $527.7K $1.854M
Capital Expenditures -$43.27K -$359.8K $49.09K
Free Cash Flow $865.5K $887.5K $1.805M
YoY Change -2.48% 2858.2% 25.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6541037
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Period End Date
DocumentPeriodEndDate
2020-05-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Trading Symbol
TradingSymbol
CCEL
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8419565
CY2019Q4 us-gaap Goodwill
Goodwill
1941411
CY2020Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
905429
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
904053
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6097331
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
684875
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
500260
CY2020Q2 us-gaap Inventory Net
InventoryNet
1053835
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7545613
dei Security Exchange Name
SecurityExchangeName
NONE
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Security12b Title
Security12bTitle
Common Stock
CY2019Q4 us-gaap Inventory Net
InventoryNet
1084533
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
241878
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
260397
CY2020Q2 us-gaap Assets Current
AssetsCurrent
17280039
CY2019Q4 us-gaap Assets Current
AssetsCurrent
15387611
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1738624
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1846467
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1215421
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1249254
CY2020Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
12382936
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12646000
CY2020Q2 us-gaap Goodwill
Goodwill
1941411
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9079994
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9079994
CY2020Q2 ccel Deposits And Other Assets
DepositsAndOtherAssets
462763
CY2019Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
427423
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25821949
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25652082
CY2020Q2 us-gaap Assets
Assets
44840612
CY2019Q4 us-gaap Assets
Assets
42886160
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
951852
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1369111
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1938826
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2085180
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8875138
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15098737
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15429429
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23633373
CY2020Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3471068
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3495057
CY2020Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2019Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34724670
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34409582
CY2020Q2 us-gaap Liabilities
Liabilities
49823407
CY2019Q4 us-gaap Liabilities
Liabilities
49839011
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q2 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35918827
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
136336
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
135989
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36248232
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20804006
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22444310
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-4982795
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44840612
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42886160
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15492618
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2763923
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2584091
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13633638
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7545613
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13598909
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7510884
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15622964
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4983687
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5094518
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7428597
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7393229
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15543
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10841
us-gaap Depreciation And Amortization
DepreciationAndAmortization
87524
us-gaap Depreciation And Amortization
DepreciationAndAmortization
112314
us-gaap Costs And Expenses
CostsAndExpenses
12491362
us-gaap Costs And Expenses
CostsAndExpenses
14272738
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
732
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2026
us-gaap Interest Expense
InterestExpense
730670
us-gaap Interest Expense
InterestExpense
831212
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-728562
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-865066
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2272694
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
485160
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
632390
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
155610
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8120454
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1549998
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8422142
us-gaap Profit Loss
ProfitLoss
1640304
us-gaap Profit Loss
ProfitLoss
329550
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
190872
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
208300
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-23989
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-670927
us-gaap Share Based Compensation
ShareBasedCompensation
288752
us-gaap Share Based Compensation
ShareBasedCompensation
225809
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
401679
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
385362
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
46818
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
57999
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
278805
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
276700
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
184615
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
148766
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-293762
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-10915
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-18519
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
23678
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
35340
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-49145
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-417259
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-232654
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-146354
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1719371
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1643589
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1818095
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3437755
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2381722
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50228
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
408870
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50228
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-408870
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1549999
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5700
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1508999
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1544298
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1878528
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
428554
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1032
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7871844
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8127852
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2480543
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2628291
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3558568
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3647927
CY2019Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2020Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
27423
CY2019Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1037984
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9821
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4957
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
43303
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6040033
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8839718
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8365284
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
25312382
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20317231
CY2019Q1 ccel Cumulative Effect Adjustment From Accumulated Other Comprehensive Income To Retained Earnings
CumulativeEffectAdjustmentFromAccumulatedOtherComprehensiveIncomeToRetainedEarnings
341000
CY2019Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
31000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
36000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
55334
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
6119658
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
7631288
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
105
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1040
CY2020Q2 us-gaap Interest Expense
InterestExpense
365371
CY2019Q2 us-gaap Interest Expense
InterestExpense
424287
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-418838
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-391948
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1333348
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
104616
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
380010
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50943
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8112289
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8421236
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6468587
CY2019Q2 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
-340984
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
34152100
CY2020Q2 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
8839718
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2020Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
11609
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
23144
CY2018Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
329231
CY2018Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
66533
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
433875
CY2019Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
329231
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5974457
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5867335
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2019Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
131351
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-6000627
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
64494
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6952851
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
288752
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-8234292
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
86827
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-8093792
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-8908298
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5700
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
225809
us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
253447
CY2019Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
7826
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
14469
CY2020Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
22481
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
45801
CY2019Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
23534
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
44488
CY2020Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
54000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
1000
CY2020Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2020Q2 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2
CY2020Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2020Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
23737
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
19416
ccel Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-131185
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
ccel Operating Leaseright Of Useasset Recorded Due To Adoption Of Asc842
OperatingLeaserightOfUseassetRecordedDueToAdoptionOfAsc842
562775
CY2020Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
431590
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
142423
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
284846
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2019Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
431424
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
268341
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
163249
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1376
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-35880
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1376
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-35880
ccel Operating Lease Liability Recorded Due To Adoption Of Asc842
OperatingLeaseLiabilityRecordedDueToAdoptionOfAsc842
562775
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
87000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1752186
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
496564
CY2020Q2 us-gaap Interest Expense
InterestExpense
365371
CY2019Q2 us-gaap Interest Expense
InterestExpense
424287
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
380010
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50943
us-gaap Operating Income Loss
OperatingIncomeLoss
3001256
us-gaap Operating Income Loss
OperatingIncomeLoss
1350226
us-gaap Interest Expense
InterestExpense
730670
us-gaap Interest Expense
InterestExpense
831212
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
632390
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
155610
CY2020Q2 ccel Inventory Collection Kits
InventoryCollectionKits
48592
CY2019Q4 ccel Inventory Collection Kits
InventoryCollectionKits
44453
CY2020Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2020Q2 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13436771
CY2019Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13730533
CY2020Q2 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod
30000
CY2020Q2 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cash Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCashPayments
444000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
125234
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
44969
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
74333
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.51
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
95870
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
5.00
CY2020Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1114743
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y8M8D
CY2020Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.49
CY2020Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1018873
CY2020Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
3.11
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2020Q2 us-gaap Notes Payable
NotesPayable
7558433
CY2019Q4 us-gaap Notes Payable
NotesPayable
9108433
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
953338
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
53673
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7545613
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7803333
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
566676
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
617903
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2020Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
105462
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
152281
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
7452971
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
8956152
CY2020Q2 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2020Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
4352971
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5856152
CY2020Q2 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1215421
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1249254
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
34000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
54000
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
81604
us-gaap Interest Expense Debt
InterestExpenseDebt
191384
CY2020Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
22337
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
46818
CY2020Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
103941
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
238202
CY2019Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
181440
us-gaap Interest Expense Debt
InterestExpenseDebt
361682
CY2019Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
28106
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
58000
CY2019Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
209546
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
419682
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7543376
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7802344
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
577078
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
619798
us-gaap Net Income Loss
NetIncomeLoss
1640304
us-gaap Net Income Loss
NetIncomeLoss
329550
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2020Q2 us-gaap Line Of Credit
LineOfCredit
350000
CY2020Q2 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000
ccel Covid19
Covid19
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration:underline;display:inline;">Note 13 &#8211; COVID 19 </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">In March 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;)</div> outbreak.&#160;The Company faces various risks related to health epidemics, pandemics and similar outbreaks, including the global outbreak of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The Company believes it has taken appropriate steps to minimize the risk to our employees and to maintain normal business operations but cannot at this time predict the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. It could have a material adverse effect on the business, financial position, results of operations and/or cash flows. Operating results for the six months ended May&#160;31, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending November&#160;30, 2020. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1500
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
64886
us-gaap Operating Lease Payments
OperatingLeasePayments
131186
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company&#8217;s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021.
CY2019Q2 us-gaap Cumulative Effect On Retained Earnings Tax1
CumulativeEffectOnRetainedEarningsTax1
94192
us-gaap Cumulative Effect On Retained Earnings Tax1
CumulativeEffectOnRetainedEarningsTax1
94192
CY2020Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-53572
CY2019Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
31299
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
289000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
226000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Warranty and Cryo-Cell Cares<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">TM</div> Program </div></div></div><div style="text-indent: 4%;font-family: times new roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#160;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June&#160;1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myelo<div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>blative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. </div></div><div style="text-indent: 4%;font-family: times new roman;font-size: 10pt;margin-top: 12pt;margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits at May&#160;31, 2020.&#160;&#160;&#160;&#160;At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes

Files In Submission

Name View Source Status
0001193125-20-191169-index-headers.html Edgar Link pending
0001193125-20-191169-index.html Edgar Link pending
0001193125-20-191169.txt Edgar Link pending
0001193125-20-191169-xbrl.zip Edgar Link pending
ccel-20200531.xml Edgar Link completed
ccel-20200531.xsd Edgar Link pending
ccel-20200531_cal.xml Edgar Link unprocessable
ccel-20200531_def.xml Edgar Link unprocessable
ccel-20200531_lab.xml Edgar Link unprocessable
ccel-20200531_pre.xml Edgar Link unprocessable
d919304d10q.htm Edgar Link pending
d919304dex311.htm Edgar Link pending
d919304dex312.htm Edgar Link pending
d919304dex313.htm Edgar Link pending
d919304dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending